105 - Slow and Steady: Insights Into Nontuberculous Mycobacteria and Treatment

Friday, October 21, 2022

8:00 AM – 9:00 AM US ET

Location: 209 ABC

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Moderator(s)

Anne-Catrin Uhlemann, MD, PhD

Associate Professor of Medicine
Columbia University Irving Medical Center
New York, NY, United States

Disclosure(s): Merck: Grant/Research Support (Ongoing)
Luiz Bermudez, MD

Professor
Oregon State University
Corvallis, OR, United States

Disclosure(s): No financial relationships to disclose

Faculty(s)

Charles Daley, MD

Professor and Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Denver, CO, United States

Disclosure(s): AN2 Therapeutics, Inc.: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); AztraZeneca: Advisor/Consultant (Ongoing); Bugworks Research, Inc.: Grant/Research Support (Ongoing); Genentech: Advisor/Consultant (Ongoing); Hyfe: Advisor/Consultant (Ongoing); Insmed Inc: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); NobHill Therapeutics: Advisor/Consultant (Ongoing); Paratek Pharmaceuticals: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer, Inc.: Advisor/Consultant (Ongoing); Renovion: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Spero Therapeutics,: Advisor/Consultant (Ongoing)

Slides
Keira Cohen, MD (she/her/hers)

Senior Medical Director
Division of Pulmonary and Critical Care Medicine
Janssen Pharmaceuticals
Baltimore, MD, United States

Disclosure(s): AN2 Therapeutics, Inc.: Advisor/Consultant (Terminated); Hill-Rom, Inc: Advisor/Consultant (Terminated), Grant/Research Support (Terminated); Insmed Inc: Advisor/Consultant (Terminated), Grant/Research Support (Terminated); Janssen Pharmaceutical Company of J&J: Employee (Ongoing); Microbion, Inc: Advisor/Consultant (Terminated); Paratek Pharmaceuticals: Advisor/Consultant (Terminated)

Slides

Disclosure(s):

Anne-Catrin Uhlemann, MD, PhD: Merck: Grant/Research Support (Ongoing)

Luiz Bermudez, MD: No financial relationships to disclose

Charles L. Daley, MD: AN2 Therapeutics, Inc.: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); AztraZeneca: Advisor/Consultant (Ongoing); Bugworks Research, Inc.: Grant/Research Support (Ongoing); Genentech: Advisor/Consultant (Ongoing); Hyfe: Advisor/Consultant (Ongoing); Insmed Inc: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); NobHill Therapeutics: Advisor/Consultant (Ongoing); Paratek Pharmaceuticals: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer, Inc.: Advisor/Consultant (Ongoing); Renovion: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Spero Therapeutics,: Advisor/Consultant (Ongoing)

Keira A. Cohen, MD: AN2 Therapeutics, Inc.: Advisor/Consultant (Terminated); Hill-Rom, Inc: Advisor/Consultant (Terminated), Grant/Research Support (Terminated); Insmed Inc: Advisor/Consultant (Terminated), Grant/Research Support (Terminated); Janssen Pharmaceutical Company of J&J: Employee (Ongoing); Microbion, Inc: Advisor/Consultant (Terminated); Paratek Pharmaceuticals: Advisor/Consultant (Terminated)

CME Credits: Maximum of 1 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1 hours of MOC Credit
CNE Credits: Maximum of 1 hours of ANCC Credit
ACPE Credits: ACPE 1 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-0000-22-002-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe novel approaches to treating NTM infections;
identif drug resistance in M. abscessus

Presentations:

8:00 AM – 8:30 AM US ET

What's New in the Treatment of NTM Infections
Speaker: Charles L. Daley, MD – National Jewish Health
8:30 AM – 9:00 AM US ET

Evolution of Drug Resistance in Mycobacterium abscessus
Speaker: Keira A. Cohen, MD (she/her/hers) – Janssen Pharmaceuticals